Discovery of potential prognostic long non-coding RNA biomarkers for predicting the risk of tumor recurrence of breast cancer patients

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhou, Meng ^a   Zhong, Lei ^b   Xu, Wanying ^a   Sun, Yifan ^a   Zhang, Zhaoyue ^a   Zhao, Hengqiang ^a   Yang, Lei ^a   Sun, Jie ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LONG UNTRANSLATED RNA; RNA; TRANSCRIPTOME; TUMOR MARKER;

BREAST TUMOR; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TUMOR RECURRENCE; VALIDATION STUDY;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RNA, LONG NONCODING; RNA, NEOPLASM; TRANSCRIPTOME;

EID: 84981206974     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31038     Document Type: Article

References (63)

1. Eddy, S. R. Non-coding RNA genes and the modern RNA world. Nat Rev Genet 2, 919-929, doi: 10.1038/35103511 (2001).
2. Wang, Y. et al. Mammalian ncRNA-disease repository: a global view of ncRNA-mediated disease network. Cell Death Dis 4, e765, doi: 10.1038/cddis.2013.292 (2013).
3. Spizzo, R., Almeida, M. I., Colombatti, A. & Calin, G. A. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene 31, 4577-4587, doi: 10.1038/onc.2011.621 (2012).
4. Guttman, M. et al. Ab initio reconstruction of cell type-specifc transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nat Biotechnol 28, 503-510, doi: 10.1038/nbt.1633 (2010).
5. Ramskold, D., Wang, E. T., Burge, C. B. & Sandberg, R. An abundance of ubiquitously expressed genes revealed by tissue transcriptome sequence data. PLoS Comput Biol 5, e1000598, doi: 10.1371/journal.pcbi.1000598 (2009).
6. Fatima, R., Akhade, V. S., Pal, D. & Rao, S. M. Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets. Mol Cell Ter 3, 5, doi: 10.1186/s40591-015-0042-6 (2015).
7. Dinger, M. E. et al. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res 18, 1433-1445, doi: 10.1101/gr.078378.108 (2008).
8. Clemson, C. M. et al. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell 33, 717-726, doi: 10.1016/j.molcel.2009.01.026 (2009).
9. Mattick, J. S., Amaral, P. P. , Dinger, M. E., Mercer, T. R. & Mehler, M. F. RNA regulation of epigenetic processes. Bioessays 31, 51-59, doi: 10.1002/bies.080099 (2009).
10. Tripathi, V. et al. Te nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 39, 925-938, doi: 10.1016/j.molcel.2010.08.011 (2010).
11. Gibb, E. A. et al. Human cancer long non-coding RNA transcriptomes. PLoS One 6, e25915, doi: 10.1371/journal.pone.0025915 (2011).
12. Ji, P. et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22, 8031-8041, doi: 10.1038/sj.onc.1206928 (2003).
13. Zhou, Y., Zhang, X. & Klibanski, A. MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol 48, R45-53, doi: 10.1530/JME-12-0008 (2012).
14. Qiu, M. T., Hu, J. W. , Yin, R. & Xu, L. Long noncoding RNA: an emerging paradigm of cancer research. Tumour Biol 34, 613-620, doi: 10.1007/s13277-013-0658-6 (2013).
15. Crea, F. et al. Identifcation of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 5, 764-774, doi: 10.18632/oncotarget.1769 (2014).
16. Zhou, M. et al. A potential signature of eight long non-coding RNAs predicts survival in patients with non-small cell lung cancer. J Transl Med 13, 231, doi: 10.1186/s12967-015-0556-3 (2015).
17. Zhou, M. et al. Identifcation and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. J Exp Clin Cancer Res 34, 102, doi: 10.1186/s13046-015-0219-5 (2015).
18. Zhou, M. et al. Characterization of long non-coding RNA-associated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer. Oncotarget doi: 10.18632/oncotarget.7181 (2016).
19. Yang, G., Lu, X. & Yuan, L. LncRNA: a link between RNA and cancer. Biochim Biophys Acta 1839, 1097-1109, doi: 10.1016/j. bbagrm.2014.08.012 (2014).
20. Zhou, M. et al. Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer. Oncotarget, doi: 10.18632/oncotarget.8653 (2016).
21. Zhou, M. et al. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma. Oncotarget, doi: 10.18632/oncotarget.8825 (2016).
22. Sun, J. et al. A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma. Sci Rep 6, 27842, doi: 10.1038/srep27842 (2016).
23. Sun, J. et al. Inferring novel lncRNA-disease associations based on a random walk model of a lncRNA functional similarity network. Mol Biosyst 10, 2074-2081, doi: 10.1039/c3mb70608g (2014).
24. Zhou, M. et al. Prioritizing candidate disease-related long non-coding RNAs by walking on the heterogeneous lncRNA and disease network. Mol Biosyst 11, 760-769, doi: 10.1039/c4mb00511b (2015).
25. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA: a cancer journal for clinicians 64, 9-29 (2014).
26. Knauer, M. et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 120, 655-661, doi: 10.1007/s10549-010-0814-2 (2010).
27. Cronin, M. et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53, 1084-1091, doi: 10.1373/ clinchem.2006.076497 (2007).
28. Chanrion, M. et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 14, 1744-1752, doi: 10.1158/1078-0432.CCR-07-1833 (2008).
29. Perez-Rivas, L. G. et al. A microRNA signature associated with early recurrence in breast cancer. PLoS One 9, e91884, doi: 10.1371/ journal.pone.0091884 (2014).
30. Lai, M. C. et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma afer liver transplantation. Med Oncol 29, 1810-1816, doi: 10.1007/s12032-011-0004-z (2012).
31. Chen, Y. et al. Diferential lncRNA expression profles in recurrent gliomas compared with primary gliomas identifed by microarray analysis. Int J Clin Exp Med 8, 5033-5043 (2015).
32. Yan, T. H. et al. Upregulation of the long noncoding RNA HOTAIR predicts recurrence in stage Ta/T1 bladder cancer. Tumour Biol 35, 10249-10257, doi: 10.1007/s13277-014-2344-8 (2014).
33. Li, Y. et al. NEAT expression is associated with tumor recurrence and unfavorable prognosis in colorectal cancer. Oncotarget 6, 27641-27650, doi: 10.18632/oncotarget.4737 (2015).
34. Gupta, R. A. et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071-1076, doi: 10.1038/nature08975 (2010).
35. Meng, J., Li, P. , Zhang, Q., Yang, Z. & Fu, S. A four-long non-coding RNA signature in predicting breast cancer survival. J Exp Clin Cancer Res 33, 84, doi: 10.1186/s13046-014-0084-7 (2014).
36. Sun, J. et al. A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients. Sci Rep 5, 16553, doi: 10.1038/srep16553 (2015).
37. Guo, N. L. & Wan, Y. W. Pathway-based identifcation of a smoking associated 6-gene signature predictive of lung cancer risk and survival. Artif Intell Med 55, 97-105, doi: 10.1016/j.artmed.2012.01.001 (2012).
38. Brewster, A. M. et al. Residual risk of breast cancer recurrence 5 years afer adjuvant therapy. Journal of the National Cancer Institute 100, 1179-1183 (2008).
39. Mittempergher, L. et al. A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. Mol Oncol 7, 987-999, doi: 10.1016/j.molonc.2013.07.006 (2013).
40. Zhou, X., Yin, C., Dang, Y. , Ye , F. & Zhang, G. Identifcation of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep 5, 11516, doi: 10.1038/srep11516 (2015).
41. Cao, W.-J., Wu, H.-L., He, B.-S., Zhang, Y.-S. & Zhang, Z.-Y. Analysis of long non-coding RNA expression profles in gastric cancer. World journal of gastroenterology: WJG 19, 3658 (2013).
42. Du, Z. et al. Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nature structural & molecular biology 20, 908-913 (2013).
43. Mayer, J., Blomberg, J. & Seal, R. L. A revised nomenclature for transcribed human endogenous retroviral loci. Mob DNA 2, 7, doi: 10.1186/1759-8753-2-7 (2011).
44. Liao, Q. et al. Large-scale prediction of long non-coding RNA functions in a coding-non-coding gene co-expression network. Nucleic Acids Res 39, 3864-3878, doi: 10.1093/nar/gkq1348 (2011).
45. Saxena, M. & Yeretssian, G. NOD-Like Receptors: Master Regulators of Infammation and Cancer. Front Immunol 5, 327, doi: 10.3389/fmmu.2014.00327 (2014).
46. Liang, Y. J. et al. Diferential expression profles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci USA 110, 968-4973, doi: 10.1073/pnas.1302825110 (2013).
47. He, Z., Ong, C. H., Halper, J. & Bateman, A. Progranulin is a mediator of the wound response. Nat Med 9, 225-229, doi: 10.1038/ nm816 (2003).
48. Tangkeangsirisin, W. & Serrero, G. PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells. Carcinogenesis 25, 1587-1592, doi: 10.1093/carcin/bgh171 (2004).
49. Wang, H. et al. Upregulation of progranulin by Helicobacter pylori in human gastric epithelial cells via p38MAPK and MEK1/2 signaling pathway: role in epithelial cell proliferation and migration. FEMS Immunol Med Microbiol 63, 82-92, doi: 10.1111/j.1574-695X.2011.00833.x (2011).
50. Lanzetti, L. & Di Fiore, P. P. Endocytosis and cancer: an 'insider' network with dangerous liaisons. Trafc 9, 2011-2021, doi: 10.1111/j.1600-0854.2008.00816.x (2008).
51. Clarke, C. et al. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis 34, 2300-2308, doi: 10.1093/carcin/bgt208 (2013).
52. Bos, P. D. et al. Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1009, doi: 10.1038/nature08021 (2009).
53. Loi, S. et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 107, 10208-10213, doi: 10.1073/pnas.0907011107 (2010).
54. Dedeurwaerder, S. et al. DNA methylation profling reveals a predominant immune component in breast cancers. Embo Mol Med 3, 726-741, doi: 10.1002/emmm.201100801 (2011).
55. Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264, doi: 10.1093/biostatistics/4.2.249 (2003).
56. Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. afy-analysis of Afymetrix GeneChip data at the probe level. Bioinformatics 20, 307-315, doi: 10.1093/bioinformatics/btg405 (2004).
57. Jiang, H. & Wong, W. H. SeqMap: mapping massive amount of oligonucleotides to the genome. Bioinformatics 24, 2395-2396, doi: 10.1093/bioinformatics/btn429 (2008).
58. Cheadle, C., Vawter, M. P. , Freed, W. J. & Becker, K. G. Analysis of microarray data using Z score transformation. J Mol Diagn 5, 73-81, doi: 10.1016/S1525-1578(10)60455-2 (2003).
59. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological), 289-300 (1995).
60. Lossos, I. S. et al. Prediction of survival in difuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350, 1828-1837, doi: 10.1056/NEJMoa032520 (2004).
61. Alizadeh, A. A. et al. Prediction of survival in difuse large B-cell lymphoma based on the expression of 2 genes refecting tumor and microenvironment. Blood 118, 1350-1358, doi: 10.1182/blood-2011-03-345272 (2011).
62. Heagerty, P. J., Lumley, T. & Pepe, M. S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56, 337-344 (2000).
63. Huang da, W. , Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37, 1-13, doi: 10.1093/nar/gkn923 (2009).